ACADIA Pharmaceuticals Statistics
Share Statistics
ACADIA Pharmaceuticals has 166.39M shares outstanding. The number of shares has increased by 0.98% in one year.
| Shares Outstanding | 166.39M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.31% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 164.30M |
| Failed to Deliver (FTD) Shares | 19 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 9.36M, so 5.62% of the outstanding shares have been sold short.
| Short Interest | 9.36M |
| Short % of Shares Out | 5.62% |
| Short % of Float | 5.7% |
| Short Ratio (days to cover) | 6.08 |
Valuation Ratios
The PE ratio is -83.69 and the forward PE ratio is 21.87.
| PE Ratio | -83.69 |
| Forward PE | 21.87 |
| PS Ratio | 7.06 |
| Forward PS | 2.6 |
| PB Ratio | 11.88 |
| P/FCF Ratio | -219.68 |
| PEG Ratio | n/a |
Enterprise Valuation
ACADIA Pharmaceuticals Inc. has an Enterprise Value (EV) of 5.00B.
| EV / Earnings | -81.55 |
| EV / Sales | 6.88 |
| EV / EBITDA | -73.68 |
| EV / EBIT | -68.11 |
| EV / FCF | -214.05 |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.
| Current Ratio | 2.42 |
| Quick Ratio | 2.28 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.14% and return on capital (ROIC) is -18.02%.
| Return on Equity (ROE) | -0.14% |
| Return on Assets (ROA) | -0.08% |
| Return on Capital (ROIC) | -18.02% |
| Revenue Per Employee | 1.17M |
| Profits Per Employee | -98.85K |
| Employee Count | 620 |
| Asset Turnover | 0.97 |
| Inventory Turnover | 1.28 |
Taxes
| Income Tax | 10.25M |
| Effective Tax Rate | -0.2 |
Stock Price Statistics
The stock price has increased by -39.33% in the last 52 weeks. The beta is 0.38, so ACADIA Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 0.38 |
| 52-Week Price Change | -39.33% |
| 50-Day Moving Average | 16.64 |
| 200-Day Moving Average | 16.41 |
| Relative Strength Index (RSI) | 61.03 |
| Average Volume (20 Days) | 2.07M |
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 726.44M and earned -61.29M in profits. Earnings per share was -0.37.
| Revenue | 726.44M |
| Gross Profit | 680.71M |
| Operating Income | -73.38M |
| Net Income | -61.29M |
| EBITDA | -67.83M |
| EBIT | -73.38M |
| Earnings Per Share (EPS) | -0.37 |
Balance Sheet
The company has 188.66M in cash and 57.20M in debt, giving a net cash position of 131.45M.
| Cash & Cash Equivalents | 188.66M |
| Total Debt | 57.20M |
| Net Cash | 131.45M |
| Retained Earnings | -2.43B |
| Total Assets | 976.87M |
| Working Capital | 444.34M |
Cash Flow
In the last 12 months, operating cash flow was 16.70M and capital expenditures -40.05M, giving a free cash flow of -23.35M.
| Operating Cash Flow | 16.70M |
| Capital Expenditures | -40.05M |
| Free Cash Flow | -23.35M |
| FCF Per Share | -0.14 |
Margins
Gross margin is 9.37K%, with operating and profit margins of -1.01K% and -844%.
| Gross Margin | 9.37K% |
| Operating Margin | -1.01K% |
| Pretax Margin | -703% |
| Profit Margin | -844% |
| EBITDA Margin | -9.34% |
| EBIT Margin | -10.1% |
| FCF Margin | -3.21% |
Dividends & Yields
ACAD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.01% |
| FCF Yield | -0.76% |
Analyst Forecast
The average price target for ACAD is $24, which is 30.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 30.4% |
| Analyst Consensus | Buy |
| Analyst Count | 18 |
Scores
| Altman Z-Score | 2.77 |
| Piotroski F-Score | 6 |